Stock Taper
SCREENER COMPARE ANY 2 STOCKS
CABA
CABALETTA BIO, INC.
NASDAQ
$3.47
▼ DOWN 0.29% (-0.01)

KEY STATISTICS

Market Cap$565.80 M
52w High$4.23
52w Low$1.63
Dividend Yield—
Frequency—
P/E-2.21
Volume4.86M
Shares Out.163.05M

COMPANY

LEADERSHIP

Steven A. Nichtberger
CHIEF EXECUTIVE
Steven A. Nichtberger

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 25, 2019
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
156

PRICE TARGET

Target High$32.00
Target Low$3.00
Target Median$14.00
Target Consensus$16.33

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.$1.67M
NOV
9
MON

PRICE

$3.47 ▼ DOWN 0.29% (−$0.01)
$3.40$3.45$3.50$3.559:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM3.47

About Cabaletta Bio, Inc.

https://www.cabalettabio.com ↗

Cabaletta Bio is a clinical-stage biotech developing engineered T cell therapies, like DSG3-CAART, to treat autoimmune diseases such as pemphigus vulgaris and hemophilia A by targeting pathogenic B cells.

INDUSTRY

Biotechnology

A PRODUCT CABALETTA BIO, INC. IS KNOWN FOR

rese-cel (resecabtagene autoleucel)
rese-cel (resecabtagene autoleucel)

Rese-cel is an investigational, fully human CD19 CAR T cell therapy by Cabaletta Bio, in Phase 1/2 trials, designed to eliminate B cells and treat autoimmune diseases like lupus, myositis, and systemic sclerosis.

COMPETITORS

COMPETITOR
BMY COMPARE
GILD COMPARE
KYTX COMPARE
NVS COMPARE
RNAC COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
81
LISTED HERE
15
RANKED BY POSITION SIZE
XBI
0.17% · 5.6M
VTS.AX
0.00% · 5.2M
IWM
0.01% · 2.9M
FESM
0.07% · 1.3M
DFAS
0.01% · 334.5K
SURI
1.08% · 272.7K
LABU
0.11% · 187.0K
PRFZ
0.02% · 179.8K
BBC
0.71% · 104.2K
XRS2.DE
0.01% · 100.3K
RSSL
0.01% · 53.2K
BIB
0.02% · 5.8K
PWS
0.03% · 2.4K
PQ
PQSV
0.08% · 1.5K
RESM
0.02% · 280

INSTITUTIONAL OWNERSHIP

SHARES OWNED
43.58%
HOLDERS
135
TOP 12 OF 135 · RANKED BY POSITION SIZE
T. Rowe Price Investment Management, Inc.
11.1M sh · $29.81M
Bain Capital Life Sciences Investors, LLC
9.7M sh · $21.19M
Jennison Associates LLC
9.0M sh · $24.13M
Adage Capital Partners Gp, L.L.C.
8.8M sh · $23.75M
Millennium Management LLC
5.9M sh · $15.88M
Cormorant Asset Management, LP
5.5M sh · $14.79M
Alyeska Investment Group, L.P.
4.8M sh · $7.3M
Blackrock Inc.
4.8M sh · $35.58M
Vanguard Group Inc
4.4M sh · $9.68M
Two Sigma Investments, LP
2.5M sh · $6.72M
Blackrock, Inc.
2.4M sh · $6.38M
Superstring Capital Management LP
2.3M sh · $4.94M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
DIRECTOR
Brun Scott C.
Purchase · 22.0K shares
2026-06-09
★
DIRECTOR
Simon Mark
Purchase · 22.0K shares
2026-06-09
★
DIRECTOR
Tomasello Shawn
Purchase · 22.0K shares
2026-06-09
★
DIRECTOR
Bollard Catherine
Purchase · 22.0K shares
2026-06-09

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
OVERWEIGHT 2
EQUAL WEIGHT 1
5 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Wells Fargo EQUAL WEIGHT Cantor Fitzgerald OVERWEIGHT Guggenheim BUY Morgan Stanley OVERWEIGHT

SECTORS PEERS

PEERPRICE
ALLO$1.97COMPARE
CAPR$9.40COMPARE
KYTX$8.25COMPARE
EDIT$3.23COMPARE
AVIR$5.83COMPARE
LXEO$4.89COMPARE
LYEL$14.37COMPARE
PRQR$2.07COMPARE